Corcept Therapeutics Incorporated CORT announced that the pivotal phase III GRACE study, which evaluated its lead pipeline candidate, relacorilant, for treating patients with Cushing’s syndrome, met ...
Source LinkCorcept Therapeutics Incorporated CORT announced that the pivotal phase III GRACE study, which evaluated its lead pipeline candidate, relacorilant, for treating patients with Cushing’s syndrome, met ...
Source Link
Comments